全球生物製药市场：市场规模和占有率分析 - 趋势、驱动因素、竞争格局和预测（2024-2030）

主要亮点

2023年全球生物製药市场规模将达4,481亿美元，2030年将达7,451亿美元，复合年增长率超过7.4%。生物製药的研发和治疗接受度的提高正在推动产业扩张。

自推出抗 TNF 生物相似药以来，欧洲的平均成本已降低约 8%，G-CSF 和促红血球生成素生物相似药则降低了 33-34%。这有助于生物製药获得广泛接受。生物製药的功效和安全性已迅速被大众接受。

许多组织和公司都专注于与生物製药相关的研发，每年的NDA/BLA註册数量都在大幅增加。特别是，由于传染病、神经系统疾病和癌症的增加，生物製药的重要性日益增加。

市场洞察

2023 年，北美地区占该产业最大占有率，约 45%。

这是由于研发资金的可用性、技术改进解决方案的接受度提高、国际公司的存在以及对获得新专利的重视。美国在该大陆引领该产业。

2023年，肿瘤领域将引领产业，约占40%占有率。近年来，生物製药在癌症试验中占据主导地位，超过了非癌症疾病试验。

未来几年，细胞和基因治疗将以最快的复合年增长率成长。该领域已经取得了一些进展，先进的研究应用于各种治疗领域的临床试验，包括细胞和基因治疗以及精准药物等标靶治疗。

单株抗体将在2023年占据产业最大占有率，达到35%，并在这十年内以约7.2%的CAGR进一步提升。单株抗体 (mAb) 是最重要的一类生物製剂，占 FDA 核准的治疗候选药物的 20% 以上。一些单株抗体被批准用于抗发炎、抗癌和其他治疗用途。正是由于它广泛应用于癌症治疗，在英国、美国等已开发国家越来越受欢迎。

本报告分析了全球生物製药市场，包括市场的基本结构和最新情况、主要促进和限制因素以及全球、依地区和主要国家的市场规模（数量和金额）前景。依产品类型和治疗用途划分的详细趋势、当前市场竞争状况以及主要公司概况。

目录

第一章研究范围

第二章研究方法

第 3 章执行摘要

第 4 章市场指标

第五章产业展望

• 市场动态
  • 趋势
  • 促进因素
  • 抑制因素/课题
  • 促进/抑制因子影响分析
• 新型冠状病毒感染 (COVID-19) 的影响
• 波特五力分析

第六章世界市场

• 摘要
• 市场收入：依产品类型划分（2017-2030 年）
• 市场收入：依治疗应用分类（2017-2030 年）
• 市场收入：依地区划分（2017-2030 年）

第七章北美市场

• 摘要
• 市场收入：依产品类型划分（2017-2030 年）
• 市场收入：依治疗应用分类（2017-2030 年）
• 市场收入：依国家/地区划分（2017-2030 年）

第8章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第十一章中东非洲市场

第12章美国市场

• 摘要
• 市场收入：依产品类型划分（2017-2030 年）
• 市场收入：依治疗应用划分（2017-2030 年）

第十三章加拿大市场

第14章德国市场

第十五章法国市场

第十六章英国市场

第十七章义大利市场

第十八章西班牙市场

第十九章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第28章阿联酋市场

第29章竞争态势

• 市场参与者及其产品列表
• 主要公司的竞争基准
• 各大公司的产品基准
• 近期策略发展状况

第30章公司简介

• Johnson & Johnson Inc.
• F. Hoffmann-La Roche AG
• Pfizer Inc
• Merck & Co. Inc.
• AbbVie Inc.
• Sanofi SA
• Eli Lilly and Company
• Abbott Laboratories
• AstraZeneca plc
• Novartis AG
• Biogen Inc.

第31章附录

Key Highlights

The biopharmaceutical market generated a value of USD 448.1 billion in 2023, which will rise to USD 745.1 billion, powering at more than 7.4% compound annual growth rate, by 2030.

The surging elderly populace, the incidence of associated health problems, and the rising need for better biologic drugs are likely to create a healthy growth environment for the players.

The rising research and development as well as therapeutic acceptance of bio-based medications are driving industry expansion.

Since the introduction of biosimilars for anti-TNF products, average costs in Europe have reduced by around 8%, while biosimilars for G-CSF and erythropoietin have reduced by 33-34%.

This has aided the extensive acceptance of biopharmaceuticals. The effectiveness and safety of bio-based medications have resulted in their quick acceptance by people.

Many organizations and businesses are concentrating on R&D related to biological drugs. The number of NDAs/ BLAs registered per year has significantly increased.

With the increasing incidence of infectious diseases, neurological disorders, and cancer, the importance of biopharmaceuticals is rising.

They are utilized for treating neurodegenerative disorders, many of which necessitate bio-medications to be administered into the brain directly, which is not possible with conventional synthetic agents.

Market Insights

North America accounted for the largest share of the industry in 2023, of approximately 45%.

This is because of the high R&D funding, increasing acceptance of technologically improved solutions, the existence of international players, and their emphasis on coming up with newer patents. The U.S. led the industry in this continent.

With the development of conventional pharma sciences and biotechnology, the consciousness about the best treatments with fewer side effects has also surged.

The U.S. leads the worldwide biopharmaceutical research and development list with over 150,000 studies performed since 2008, due to the size and prominence of its pharmaceutical industry.

In the U.S., California accounts for the most studies, partly, due to its strong tech sector as well as its desire for innovation.

Oncology led the industry in 2023, with a share of approximately 40%. In the past few years, biopharmaceuticals have been dominant in cancer trials than trials for non-cancer conditions.

Cell and gene therapies will grow at the fastest compound annual growth rate in the years to come.

There have been several improvements in this area, representing advanced research, which is being employed in clinical trials in different therapeutic fields, such as cell & gene therapies and targeted therapies like precision drugs.

Monoclonal antibodies accounted for the largest share of the industry in 2023, of 35%, and it will further propel at approximately 7.2% CAGR during this decade.

Monoclonal antibodies (mAbs) are the most significant class of biologics, which account for over 20% of all the therapeutic candidates approved by the FDA.

Some mAbs have been permitted for anti-inflammatory, anti-cancer, and additional therapeutic applications. Precisely, because of their widespread utilization in cancer treatment, they are becoming widespread in developed nations like the U.K. and the U.S.

The biopharmaceutical industry is characterized by strong competition among mid-sized firms, large global firms, and new biotech firms.

Major factors boosting the competition are innovative R&D, regulatory compliance, market access, and product differentiation.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product type
  • 1.4.2. Market size breakdown, by therapeutic application
  • 1.4.3. Market size breakdown, by region
  • 1.4.4. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product Type (2017-2030)
• 6.3. Market Revenue, by Therapeutic Application (2017-2030)
• 6.4. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product Type (2017-2030)
• 7.3. Market Revenue, by Therapeutic Application (2017-2030)
• 7.4. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product Type (2017-2030)
• 8.3. Market Revenue, by Therapeutic Application (2017-2030)
• 8.4. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product Type (2017-2030)
• 9.3. Market Revenue, by Therapeutic Application (2017-2030)
• 9.4. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product Type (2017-2030)
• 10.3. Market Revenue, by Therapeutic Application (2017-2030)
• 10.4. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product Type (2017-2030)
• 11.3. Market Revenue, by Therapeutic Application (2017-2030)
• 11.4. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product Type (2017-2030)
• 12.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product Type (2017-2030)
• 13.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product Type (2017-2030)
• 14.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product Type (2017-2030)
• 15.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product Type (2017-2030)
• 16.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product Type (2017-2030)
• 17.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product Type (2017-2030)
• 18.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product Type (2017-2030)
• 19.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product Type (2017-2030)
• 20.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product Type (2017-2030)
• 21.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product Type (2017-2030)
• 22.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product Type (2017-2030)
• 23.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product Type (2017-2030)
• 24.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product Type (2017-2030)
• 25.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product Type (2017-2030)
• 26.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product Type (2017-2030)
• 27.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product Type (2017-2030)
• 28.3. Market Revenue, by Therapeutic Application (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Johnson & Johnson Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. F. Hoffmann-La Roche AG
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Pfizer Inc
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Merck & Co. Inc.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. AbbVie Inc.
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Sanofi SA
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Eli Lilly and Company
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Abbott Laboratories
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. AstraZeneca plc
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Novartis AG
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary
• 30.11. Biogen Inc.
  • 30.11.1. Business overview
  • 30.11.2. Product and service offerings
  • 30.11.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports